Brookline last night initiated coverage of SAB Biotherapeutics with a Buy rating and $8 price target. SAB is developing SAB-142 as a potential disease-modifying therapy that can delay the onset and progression of clinical stage 3 type 1 diabetes, the analyst tells investors in a research note. The firm sees a favorable risk/reward as SAB-142 advances through the clinic “as there is a significant unmet need for scalable, efficacious, and safe immunotherapies.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SABS:
- SAB Biotherapeutics Appoints Mr. Conley, Details Public Disclosure
- SAB Biotherapeutics Announces Departure of Chief Financial Officer
- FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
- SAB Biotherapeutics announces FDA clearance for SAB-142 IND application
- SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue